

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

October 30, 2024

Singapore Exchange Securities Trading Limited
4 Shenton Way # 02-01
SGX Centre 2 Singapore 068807

Dear Sir,


Subject: Company Statement

Please find enclosed the company statement titled **"Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)"**.


Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand
Company Secretary
Membership No. ACS 13669



Encl: as above

NOTIFICATION TO STOCK EXCHANGE**COMPANY STATEMENT****Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)**

Bengaluru, Karnataka, India, Oct 30, 2024

"The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Drug Substance Facility at Biocon Campus, (Site 1) located in Bengaluru, Karnataka, as Voluntary Action Indicated (VAI).

This relates to the cGMP inspection conducted by the agency between February 20-28, 2024 and pertains to the supply of rh-Insulin (rhl) Drug Substance to the United States.

Biocon Biologics remains committed to global standards of Quality and Compliance."

– Company Spokesperson